首页> 外文期刊>Retina >Treatment of choroidal neovascularization due to angioid streaks: A comprehensive review
【24h】

Treatment of choroidal neovascularization due to angioid streaks: A comprehensive review

机译:综合治疗:血管纹状脉络膜脉络膜新生血管的治疗

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To evaluate different therapies for choroidal neovascularization (CNV) due to angioid streaks (AS). METHODS: Studies were identified by a systematic literature search and were included in the analysis based on predefined criteria. Primary outcome measure was change in best-corrected visual acuity (BCVA). RESULTS: Fifty-four relevant studies were identified and included mostly uncontrolled case series. No randomized controlled trials were available. Treatment with vascular endothelial growth factor inhibitors improved or stabilized BCVA in all case series. Photodynamic therapy slowed down disease progression with stabilization or decrease of BCVA. Individual BCVA and follow-up data for each treated eye were reported in >160 cases for both treatments, vascular endothelial growth factor inhibitors and photodynamic therapy. In a pooled analysis of those studies, the difference of mean change in BCVA between both treatment groups was estimated as approximately 6 lines (0.59 logMAR [95% confidence interval, 0.38-0.8; P < 0.0001]). A better baseline BCVA was associated with a better BCVA outcome (P < 0.0001). Laser photocoagulation yielded comparable results as photodynamic therapy but application was mostly restricted to extrafoveal lesions, was complicated by frequent recurrences, and led to more retinal damage with subsequent absolute scotomas. Combination therapies seem to be not superior to monotherapy. CONCLUSION: Intravitreal vascular endothelial growth factor inhibitors are currently the most effective treatment of CNV due to angioid streaks.
机译:目的:评估由于血管纹(AS)引起的脉络膜新生血管形成(CNV)的不同疗法。方法:通过系统的文献检索对研究进行鉴定,并根据预定标准将其纳入分析。主要结局指标是最佳矫正视力(BCVA)的变化。结果:确定了54项相关研究,其中大部分是不受控制的病例系列。没有随机对照试验。在所有情况下,使用血管内皮生长因子抑制剂治疗均可改善或稳定BCVA。光动力疗法通过稳定或降低BCVA减慢了疾病进展。两种治疗方法,血管内皮生长因子抑制剂和光动力疗法均报道了> 160例患者的每只经治疗眼睛的单独BCVA和随访数据。在对这些研究的汇总分析中,两个治疗组之间BCVA的平均变化差异估计约为6行(0.59 logMAR [95%置信区间,0.38-0.8; P <0.0001])。更好的基线BCVA与更好的BCVA结果相关(P <0.0001)。激光光凝术产生的结果与光动力疗法相当,但应用仅限于中央凹外病变,并因频繁复发而复杂化,并导致更多的视网膜损伤和随后的绝对性近视。联合疗法似乎并不优于单一疗法。结论:玻璃体内血管内皮生长因子抑制剂是目前最有效的治疗CNV的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号